CardioGenesis Closes Private Placement With Wisconsin Investment Board
FOOTHILL RANCH, Calif., Dec. 28 -- CardioGenesis Corp. has announced the closing of a $2.0 million private placement of its common stock with the State of Wisconsin Investment Board. The private placement involved 2,222,225 shares of CardioGenesis common stock at a fixed price and terms agreed in mid-December.
CardioGenesis is a medical device company specializing in the treatment of cardiovascular disease and is the leader in products that stimulate cardiac angiogenesis. The company's Holmium:YAG laser system and disposable fiber optic accessories are used to perform an FDA-cleared surgical procedure known as transmyocardial revascularization to treat patients suffering from angina.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024